Navigation Links
Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
Date:1/28/2010

tive compensation, as a means to evaluate period-to-period comparisons, as well as comparisons to our competitors' operating results.  Management also uses this information internally for forecasting and budgeting, as it believes that the measures are indicative of Thoratec core operating results.  Management also believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company's business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist in analyzing future trends.

Non-GAAP net income consists of GAAP net income, excluding, as applicable, the tax effected impact of share-based compensation expense, amortization of purchased intangibles, expenses associated with the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements in accordance with Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") 470-20, Debt, HeartWare transaction costs, and unrealized gains on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP net income per diluted share is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis.  

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense.    

Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, amortization of purchased intangibles, and HeartWare transaction costs.

Non-GAAP other income and expense consists of
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
5. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
6. Thoratec Presentation at Canaccord Adams Conference to be Webcast
7. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
8. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
9. Thoratec Presentation at Piper Jaffray Conference to be Webcast
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:9/1/2015)... ... ... new episode of “Voices In America”, hosted by famous actor and voice over specialist ... over 100 different types of arthritis. One of the most popular is rheumatoid arthritis. ... light on this important topic. , Anyone who is nearing their golden years or ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... leading retailer of professional hair salons. This highly anticipated partnership between Curly Hair ... Curl Keeper™ Styling Collection. Founder Jonathan Torch and the Curly Hair Solutions™ team ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces ... and Influence by Modern Luxury’s The Atlantan Magazine. , This award for ... Kathy King. Her idea and vision to bring to Atlanta a true luxury ...
(Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... When it comes to undergoing ... to the top of the head. Adding more volume to the hair on top ... procedure for patients who have a good amount of donor hair on other areas of ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... new weight management program that is unique to the Lake Orion area. This ... and Macomb County. , WEmovestrong’s weight management program will incorporate group fitness ...
Breaking Medicine News(10 mins):Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2
... Savings Program launches in AR, AZ, CO, FL, LA, ... Albertson,s LLC announced its new,Albertsons Rx-tra Savings prescription discount ... all generic and brand name,medications -- including up to ... $4.99. The membership-based program will be offered in all ...
... times on the horizon, dentists, ,as well as all other medical ... G. Flasch, of Flasch Business Expansion. An award winning consultant with ... to expand their practices using precise business strategies. , ... ...
... MD (Oct. 1, 2008) Obese patients with a ... the weight loss drug sibutramine and undergoing behavioral therapy ... new study in Gastroenterology , the official journal ... The obesity epidemic continues to be an increasingly global ...
... joint effusion (the collection of fluid in the spinal ... ligaments) are major sources of lower back pain, according ... Ankara, Turkey and Alanya Research Center in Antalya, Turkey. ... lower back pain and 249 healthy patients underwent MRI ...
... Medical Professional to Apply Rigors,of "Evidence-Based Medicine" to Investing; ... Advice About the Best Medicine For Portfolios?, ROCKFORD, ... base their diagnoses on what the latest scientific,research shows ... and other,illnesses. Yet most financial advisors do not operate ...
... Episodes from MARTHA SPEAKS, SUPER WHY, WORDWORLD,and CYBERCHASE Help Kids ... To Prepare for the Long Holiday Season Ahead, SID THE ... Moderation, ARLINGTON, Va., Sept. 30 PBS KIDS and ... on Halloween,day and preparing for the holiday season ahead with ...
Cached Medicine News:Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 2Health News:Medical Marketing Expert Offers Dentists Tips for Thriving Down Economy After the Wall Street Dilemma 3Health News:Genes influence effectiveness of weight-loss drug 2Health News:Genes influence effectiveness of weight-loss drug 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 4Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 5Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 2Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 3Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 4Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 5
... designed for PCR amplification and target ... systems. The NGEN product line includes ... associated with cystic fibrosis, thrombosis, and ... for the detection of sequences associated ...
... pregnancy testing, our new ICON 25 hCG ... you fast, accurate results, plus Beckman Coulter ... hCG offers CLIA waived simplicity for urine ... For the hospital, it's the perfect complement ...
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: